新型冠状病毒肺炎：免疫病理学及其治疗意义。
COVID-19: immunopathology and its implications for therapy.
机构信息
Laboratory of Immunity and Inflammation, College of Life Science, Nankai University, Tianjin, China.
Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
出版信息
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
Abstract
Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.
摘要
严重的 2019 年冠状病毒病（COVID-19）的特征是肺炎、淋巴细胞减少、耗竭的淋巴细胞和细胞因子风暴。观察到显著的抗体产生；然而，这是否具有保护作用还是致病作用仍有待确定。定义 COVID-19 患者的免疫病理变化为药物发现提供了潜在的靶点，对临床管理很重要。
相似文献
1
COVID-19: immunopathology and its implications for therapy.
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
2
Passive antibody therapy in COVID-19.
Nat Rev Immunol. 2020 Jul;20(7):401-403. doi: 10.1038/s41577-020-0365-7.
3
Not just antibodies: B cells and T cells mediate immunity to COVID-19.
Nat Rev Immunol. 2020 Oct;20(10):581-582. doi: 10.1038/s41577-020-00436-4.
4
Recommendations for caring for patients with severe and nonsevere COVID-19.
Ann Intern Med. 2020 Jul 21;173(2):JC3. doi: 10.7326/ACPJ202007210-004.
5
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
Clin Transl Sci. 2020 Sep;13(5):835-837. doi: 10.1111/cts.12816. Epub 2020 Jun 26.
6
Potential strategies for combating COVID-19.
Arch Virol. 2020 Nov;165(11):2419-2438. doi: 10.1007/s00705-020-04768-3. Epub 2020 Aug 10.
7
The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.
Cell Transplant. 2020 Jan-Dec;29:963689720940719. doi: 10.1177/0963689720940719.
8
Convalescent serum lines up as first-choice treatment for coronavirus.
Nat Biotechnol. 2020 Jun;38(6):655-658. doi: 10.1038/d41587-020-00011-1.
9
Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.
Int Immunopharmacol. 2020 Nov;88:106885. doi: 10.1016/j.intimp.2020.106885. Epub 2020 Aug 8.
10
Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Signal Transduct Target Ther. 2020 Sep 15;5(1):203. doi: 10.1038/s41392-020-00310-8.
引用本文的文献
1
Effects of 1, 25-dihydroxy-vitamin D on the immune response in chicken embryo fibroblast cells infected by infectious bronchitis virus.
Poult Sci. 2025 Aug 7;104(11):105637. doi: 10.1016/j.psj.2025.105637.
2
Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.
Signal Transduct Target Ther. 2025 Aug 22;10(1):262. doi: 10.1038/s41392-025-02313-9.
3
The roles of macrophages and monocytes in COVID-19 Severe Respiratory Syndrome.
Cell Insight. 2025 May 8;4(4):100250. doi: 10.1016/j.cellin.2025.100250. eCollection 2025 Aug.
4
determination of novel SARS-CoV-2 envelope protein ion channel inhibitors.
Comput Struct Biotechnol J. 2025 Jun 26;27:2823-2831. doi: 10.1016/j.csbj.2025.06.036. eCollection 2025.
5
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.
BMC Nephrol. 2025 Jul 1;26(1):294. doi: 10.1186/s12882-025-04267-0.
6
Eco-friendly spectrofluorimetric determination of remdesivir in the presence of its metabolite in human plasma for therapeutic monitoring in COVID-19 patients.
Sci Rep. 2025 Jun 23;15(1):20251. doi: 10.1038/s41598-025-05198-4.
7
Development Of the VAMPCT Score for Predicting Mortality in CKD Patients with COVID-19.
Int J Med Sci. 2025 May 31;22(11):2782-2791. doi: 10.7150/ijms.111558. eCollection 2025.
8
State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic.
OpenNano. 2022 Nov-Dec;8:100078. doi: 10.1016/j.onano.2022.100078. Epub 2022 Sep 10.
9
Hypericin Suppresses SARS-CoV-2 Replication and Synergizes with Antivirals via Dual Targeting of RdRp and 3CLpro.
Microorganisms. 2025 Apr 27;13(5):1004. doi: 10.3390/microorganisms13051004.
10
Cellular and Molecular Atlas of Peripheral Blood Mononuclear Cells from a Pregnant Woman After Recovery from COVID-19.
Matern Fetal Med. 2023 Apr 24;5(2):88-96. doi: 10.1097/FM9.0000000000000190. eCollection 2023 Apr.
本文引用的文献
1
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.
Front Mol Biosci. 2020 Jul 3;7:157. doi: 10.3389/fmolb.2020.00157. eCollection 2020.
2
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.
Immunology. 2020 Jul;160(3):261-268. doi: 10.1111/imm.13223.
3
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.
4
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
5
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
Pharmacol Res. 2020 Jun;156:104761. doi: 10.1016/j.phrs.2020.104761. Epub 2020 Mar 20.
6
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
7
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
8
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件